TY - JOUR T1 - Review: glycoprotein IIb/IIIa inhibitors reduced death or myocardial infarction in acute coronary syndromes not routinely scheduled for revascularisation JF - Evidence Based Medicine JO - Evid Based Med SP - 108 LP - 108 DO - 10.1136/ebm.7.4.108 VL - 7 IS - 4 A2 - , Y1 - 2002/07/01 UR - http://ebm.bmj.com/content/7/4/108.abstract N2 - (2002) Lancet 359, 189; Boersma E, Harrington RA, Moliterno DJ, et al.. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials.. Jan 19;. :. –98.OpenUrlCrossRefPubMedWeb of Science
 
 QUESTION: In patients with acute coronary syndromes not routinely scheduled for early coronary revascularisation, what is the efficacy and safety of glycoprotein (GP) IIb/IIIa inhibitors? Trials reported from 1990 were identified by searching Medline with the terms unstable angina, myocardial infarction, and platelet aggregation inhibition; reviewing scientific sessions abstracts in 3 cardiology journals; and scanning bibliographies of retrieved articles. Studies were selected if they randomly allocated ≥ 1000 patients who had acute coronary syndromes without persistent ST-segment elevation to a GP IIb/IIIa inhibitor or to placebo or control treatment and if early (< 48 h) coronary revascularisation during drug infusion was not recommended. Data from individual patients were extracted on baseline characteristics (age, sex, cardiac history and medication, blood pressure, and heart rate), medication detail, dates and times of randomisation, … ER -